Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $91,637.83 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel directly owned 21,225 shares of the company’s stock, valued at approximately $679,836.75. This represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $43,637.15.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $31.40 on Friday. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of -9.40 and a beta of 1.20. Stoke Therapeutics, Inc. has a one year low of $18.00 and a one year high of $40.22. The business’s fifty day moving average is $30.94 and its 200-day moving average is $32.23.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Research analysts expect that Stoke Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Stoke Therapeutics by 12.1% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,228 shares of the company’s stock valued at $2,134,000 after buying an additional 7,043 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Stoke Therapeutics by 13.7% during the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after buying an additional 423,601 shares during the period. Palo Alto Investors LP purchased a new stake in shares of Stoke Therapeutics in the second quarter worth about $2,769,126,000. Capstone Investment Advisors LLC purchased a new stake in shares of Stoke Therapeutics in the second quarter worth about $314,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $255,353,000.

Analyst Ratings Changes

STOK has been the subject of several research analyst reports. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Wedbush upped their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Canaccord Genuity Group decreased their target price on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.